Effects of Combined Oxytocin Receptor (OTR) with Vasopressin Receptor (V1aR or V1bR) Blockade within Paraventricular Nucleus (PVN) on Neurocardiovascular Responses

被引：0
|
作者：
Rossi, Noreen [1 ,2 ]
Li, Cailian [1 ]
机构：
[1] Wayne State Univ, Internal Med & Physiol, Detroit, MI USA
[2] John D Dingell VA Med Ctr, Detroit, MI USA
来源：
FASEB JOURNAL | 2015年 / 29卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
987.2
引用
收藏
页数：1
相关论文
共 50 条
  • [31] V1-RECEPTOR AND V2-RECEPTOR CONTRIBUTIONS TO OVINE FETAL RENAL AND CARDIOVASCULAR-RESPONSES TO VASOPRESSIN
    ERVIN, MG
    ROSS, MG
    LEAKE, RD
    FISHER, DA
    AMERICAN JOURNAL OF PHYSIOLOGY, 1992, 262 (04): : R636 - R643
  • [32] Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists?
    Goldsmith, Steven R.
    AMERICAN JOURNAL OF MEDICINE, 2006, 119 : S93 - S96
  • [33] Neurohormonal antagonism in heart failure;: beneficial effects of vasopressin V1a and V2 receptor blockade and ACE inhibition
    Naitoh, M
    Risvanis, J
    Balding, LC
    Johnston, CI
    Burrell, LM
    CARDIOVASCULAR RESEARCH, 2002, 54 (01) : 51 - 57
  • [34] Vascular Effects of RWJ-676070, a Selective Combined V1a/V2 Vasopressin Receptor Antagonist
    Coltamai, L.
    Bucher, M.
    Maillard, M. P.
    Shukla, U.
    Bohidar, N.
    Haskell, L.
    Bertelsen, K.
    Fedgchin, M.
    Vogt, B.
    Burnier, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (02) : 145 - 148
  • [35] Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors
    Tahara, A
    Tsukada, J
    Tomura, Y
    Kusayama, T
    Wada, KI
    Ishii, N
    Taniguchi, N
    Suzuki, T
    Yatsu, T
    Uchida, W
    Shibasaki, M
    PHARMACOLOGICAL RESEARCH, 2005, 51 (03) : 275 - 281
  • [36] Differential responses of the vasotocin 1a receptor (V1aR) and osmoreceptors to immobilization and osmotic stress in sensory circumventricular organs of the chicken (Gallus gallus) brain
    Aman, N. Alphonse
    Nagarajan, Gurueswar
    Kang, Seong W.
    Hancock, Megan
    Kuenzel, Wayne J.
    BRAIN RESEARCH, 2016, 1649 : 67 - 78
  • [37] The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study
    Lago, Tiffany R.
    Brownstein, Michael J.
    Page, Emily
    Beydler, Emily
    Manbeck, Adrienne
    Beale, Alexis
    Roberts, Camille
    Balderston, Nicholas
    Damiano, Eve
    Pineles, Suzanne L.
    Simon, Neal
    Ernst, Monique
    Grillon, Christian
    PSYCHOPHARMACOLOGY, 2021, 238 (09) : 2393 - 2403
  • [38] BLOOD-PRESSURE-LOWERING EFFECT OF VASOPRESSIN DURING V1 RECEPTOR BLOCKADE
    HUCH, KM
    WALL, BM
    BOBAL, MA
    GAVRAS, H
    COOKE, CR
    CLINICAL RESEARCH, 1993, 41 (02): : A288 - A288
  • [39] V1a and V1b vasopressin receptors within the paraventricular nucleus contribute to hypertension in male rats exposed to chronic mild unpredictable stress
    Komnenov, Dragana
    Quaal, Harrison
    Rossi, Noreen F.
    AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2021, 320 (03) : R213 - R225
  • [40] PROLONGED VASOPRESSIN V1-RECEPTOR AGONIST EFFECTS IN THE OVINE FETUS
    ERVIN, MG
    ROSS, MG
    LEAKE, RD
    FISHER, DA
    CLINICAL RESEARCH, 1991, 39 (01): : A113 - A113
12345